Newer glucose‐lowering drugs and risk of dementia: A systematic review and meta‐analysis of observational studies
Open accessAbstract
Background: Preclinical studies have suggested potential beneficial effects of newer glucose‐lowering drugs (GLDs) including dipeptidyl peptidase (DPP)‐4 inhibitors, glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs), and sodium glucose co‐transporter‐2 (SGLT2) inhibitors, in protecting humans against cognitive decline and dementia. However, population studies aiming to demonstrate such cognitive benefits from newer GLDs have produced mixed findings. This meta‐analysis aimed to evaluate the association between newer GLDs and risk of dementia in adults with type 2 diabetes (T2D). Methods: Electronic databases were searched up to March 11, 2022 to include observational studies that examined the association between DPP‐4 inhibitors, GLP‐1RAs, and SGLT2 inhibitors and risk of dementia (including all‐cause dementia, Alzheimer's disease [AD], and vascular dementia [VD]) in people with T2D. We conducted a random‐effects meta‐analysis to calculate the relative risk (RR) with 95% confidence interval (CI) for each class of newer GLD. Results: Ten studies (from nine articles) involving 819,511 individuals with T2D were included. Three studies found that SGLT2 inhibitor users had a lower risk of all‐cause dementia than non‐SGLT2 inhibitor users (RR, 0.62; 95% CI, 0.39–0.97). Five studies found that users versus nonusers of GLP‐1RAs were associated with a significant reduction in the risk of all‐cause dementia (RR, 0.72; 95% CI, 0.54–0.97). However, a meta‐analysis for AD and VD was unavailable for SGLT2 inhibitors and GLP‐1RAs because only one study was included for each drug. In seven studies, users vs. nonusers of DPP‐4 inhibitors were significantly associated with a decreased risk of all‐cause dementia (RR, 0.84; 95% CI, 0.74–0.94) and VD (RR, 0.59; 95% CI, 0.47–0.75) but not AD (RR, 0.82; 95% CI, 0.63–1.08). Conclusion: Newer GLDs were associated with a decreased risk of all‐cause dementia in people with T2D. Because of the observational nature and significant heterogeneity between studies, the results should be interpreted with caution. Further research is warranted to confirm our findings.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
There is RCT evidence for the protective effect of GLP-1 RAs against dementia.
“There is also RCT evidence for the protective effect of GLP-1 RAs. (181)”
From Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission (2024) · cites this paper as [181]
Observational evidence suggests that certain glucose-lowering drug classes, such as SGLT2is and GLP-1RAs, may have a neuroprotective effect.
“Observational evidence suggests that certain glucose-lowering drug classes, such as SGLT2is and GLP-1RAs, may have a neuroprotective effect.8,9”
From Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis (2025) · cites this paper as [8]
A 2023 meta-analysis of randomized clinical trials did not report a significant reduction in dementia, and included 21 randomized clinical trials, including DPP-4 inhibitors, GLP1-RAs, and SGLT2is.
“A 2023 meta-analysis of randomized clinical trials did not report a significant reduction in dementia, and included 21 randomized clinical trials, including DPP-4 inhibitors, GLP1-RAs, and SGLT2is.8”
From Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis (2025) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 56 · Cited by 106
- Authors
- Tang, H., Shao, H., Shaaban, C. E., Yang, K., Brown, J., Anton, S., Wu, Y., Bress, A., Donahoo, W. T., DeKosky, S. T., Bian, J., & Guo, J.
- Affiliations
- University of Florida Health (US)
- University of Pittsburgh (US)
- Harvard University (US)
- University of Utah (US)
- University of Florida (US)
- Corresponding author
- Guo, Jingchuan
- ORCID
- Venue
- Journal of the American Geriatrics Society
- Publisher
- Wiley
- Published
- 2023-02-23
- Volume
- 71
- Issue
- 7
- Pages
- 2096-2106
- ISSN
- 0002-8614 (ISSN-L)
- 1532-5415
- PMC
- PMC10363181
- OpenAlex
- W4321607021
- Cited by
- 106
- References
- 56
- Citations by year
- 2026: 23 · 2025: 42 · 2024: 32 · 2023: 9
- FWCI
- 3.81
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of the American Geriatrics Society (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Institute on Aging (R56AG069880, K01AG071849, R01AG080991, R01AG076234)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK133465)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Keywords
- dementia risk, type 2 diabetes, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, Alzheimer's disease, vascular dementia, cognitive decline, drug safety, glycemic control, quality of life, cost-effectiveness, health-related quality of life
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Dementia, Diabetes Mellitus, Type 2, Glucose, Humans, Hypoglycemic Agents, Dipeptidyl-Peptidase IV Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review